Cargando…
An Unusual Etiology of Graves’ Disease: Alemtuzumab
Cluster of differentiation 52 (CD-52) is a glycoprotein expressed on the surface of most lymphocytes and it is the most prevalent marker in T cells, B cells, natural killers and monocytes. Alemtuzumab, a CD-52 monoclonal antibody, is one of the initial therapies approved for patients with relapsing-...
Autores principales: | Santiago Carrion, Ada Marie, Agosto-Vargas, Yanerys |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089799/ http://dx.doi.org/10.1210/jendso/bvab048.1882 |
Ejemplares similares
-
Concurrent Papillary and Follicular Thyroid Cancer Presenting as Shoulder Pain
por: Santiago Carrion, Ada Marie, et al.
Publicado: (2021) -
SAT-476 Alemtuzumab Induced Graves Disease
por: Caputi, Rafael C, et al.
Publicado: (2020) -
ODP523 Thyroid Storm in a Patient With Alemtuzumab Induced Graves’ Disease
por: AlShehri, Sara, et al.
Publicado: (2022) -
ODP482 Graves Orbitopathy Secondary to Alemtuzumab Infusion for Multiple Sclerosis
por: Alam, Mustafa, et al.
Publicado: (2022) -
SAT-518 Progression of Graves Disease to Hashimoto’s Thyroiditis Following Alemtuzumab Therapy for Multiple Sclerosis
por: Rapier, Brandon, et al.
Publicado: (2020)